Genmab A/S (GMAB) Q3 2024 Earnings Conference Call November 6, 2024 12:00 PM ET
Company Participants
Jan van de Winkel – CEO
Brad Bailey – EVP and Chief Commercial Officer
Anthony Pagano – CFO
Judith Klimovsky – Chief Development Officer
Tahamtan Ahmadi – Chief Medical Officer
Conference Call Participants
Jonathan Chang – LeeRink Partners
Paul Jeng – Guggenheim Securities, LLC
Zain Ebrahim – JPMorgan Chase
Suzanne van Voorthuizen – Kempen & Co.
Xian Deng – UBS
Yaron Werber – TD Securities
Asthika Goonewardene – Truist Securities
Yifeng Liu – HSBC
Matthew Phipps – William Blair
Alistair Campbell – RBC Capital Markets
Vikram Purohit – Morgan Stanley
Etzer Darout – BMO Capital Markets
Operator
Hello, and welcome to Genmab’s Financial Results Conference Call for the First Nine Months of 2024. As a reminder, this conference call is being recorded.
During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless this is required by law.
Please also note that Genmab may hold your personal data, as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.
I would now like to hand the conference over to your first speaker today, Jan van de Winkel. Please go ahead.
Jan van de Winkel
Hello, and welcome to Genmab’s conference call to discuss the company’s financial results for the period ending September 30, 2024.
With me today to present these results
Read the full article here
